Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
Abstract Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance with monotherapy, practical limits on numbers of treatment arms for component dose combinations, and limi...
Main Author: | Michael A. Lyons |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12591 |
Similar Items
-
Pretomanid: Clinical Trials and Prospects to Be Used in Treatment Regimens for Multiple and Extensive Drug Resistant Tuberculosis
by: A. V. Kukurika
Published: (2021-07-01) -
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
by: Amukoye, E, et al.
Published: (2021) -
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
by: Amukoye, E., et al.
Published: (2021) -
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
by: Paula J. Gómez-González, et al.
Published: (2021-09-01) -
ON THE SELECTION OF DRUGS DOSAGE REGIMEN
by: E. N. Bochanova
Published: (2015-09-01)